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Botulinum neurotoxins (BoNTs) are responsible for human botulism, a life-threatening disease characterized by
flaccid muscle paralysis that occurs naturally by food poisoning or colonization of the gastrointestinal tract by BoNT-
producing clostridia. BoNTs have been classified as category A agents by the Centers for Disease Control and
Prevention. To date, 7 subtypes of BoNT/B were identified showing that subtypes B1 (16 strains) and B2 (32 strains)
constitute the vast majority of BoNT/B strains. Neutralizing antibodies are required for the development of anti-
botulism drugs to deal with the potential risk. In this study, macaques (Macaca fascicularis) were immunized with
recombinant light chain (LC) or heavy chain (HC) of BoNT/B2, followed by the construction of 2 hyper-immune phage
display libraries. The best single-chain variable fragments (scFvs) isolated from each library were selected according to
their affinities and cross reactivity with BoNT/B1 toxin subtype. These scFvs against LC and HC were further analyzed by
assessing the inhibition of in vitro endopeptidase activity of BoNT/B1 and B2 and neutralization of BoNT/B1 and B2
toxin-induced paralysis in the mouse ex vivo phrenic nerve assay. The antibodies B2–7 (against HC) and BLC3 (against
LC) were produced as scFv-Fc, and, when tested individually, neutralized BoNT/B1 and BoNT/B2 in a mouse ex vivo
phrenic nerve assay. Whereas only scFv-Fc BLC3 alone protected mice against BoNT/B2-induced paralysis in vivo, when
B2–7 and BLC3 were combined they exhibited potent synergistic protection. The present study provided an
opportunity to assess the extent of antibody-mediated neutralization of BoNT/B1 and BoNT/B2 subtypes in ex vivo and
in vitro assays, and to confirm the benefit of the synergistic effect of antibodies targeting the 2 distinct functional
domains of the toxin in vivo. Notably, the framework regions of the most promising antibodies (B2–7 and BLC3) are
close to the human germline sequences, which suggest that they may be well tolerated in potential clinical
development.
Introduction
Botulinum neurotoxins (BoNT/s) are proteins secreted by the
anaerobic spore-forming bacteria, Clostridium botulinum, which
is responsible for the naturally-occurring lethal disease, botulism.
BoNTs are classified in 7 serotypes (A to G) where BoNT/A, B
and E are mainly implicated in natural human intoxication, with
A and B serotypes being responsible for more than 90% of the
cases.1,2 Due to their high toxicity and ease of production and
dissemination, BoNTs are also considered by the Centers for
Disease Control and Prevention as one of the major threats for
bioterrorism as a “Category A” agent.3 In fact, BoNT/A and
BoNT/B are considered to be the most toxic substances known,
with a human LD50 estimated between 1 and 10 ng.kg
¡1 by
intravenous, subcutaneous, intra-peritoneal and intramuscular
routes; between 10 and 21 ng.kg¡1 by pulmonary route and at
1 mg.kg¡1 by oral route.3-9 To date, 7 subtypes of BoNT/B
(BoNT/B1 to B7) have been identified.10,11 The analysis of 53
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Clostridium botulinum B strains showed that subtypes B1 (16
strains) and B2 (32 strains) constitute the vast majority of
BoNT/B strains. At the amino acid sequence level, BoNT/B1
and BoNT/B2 holotoxins present an overall identity of 96%,
and their heavy chains present an identity of 91%.12 BoNTs are
composed of a 100 kDa heavy chain (HC) and a 50 kDa light
chain (LC). The toxin binds to the neuronal cell surface due to
the interaction between the C-terminus of the HC and high
affinity receptors on the neural cell surface, and then penetrates
into the cell by endocytosis.13 The endosome acidification trig-
gers the translocation of the LC from the lumen of the vesicles
into the cytoplasm. The LC acts as a zinc-metalloprotease that
cleaves components of the SNARE (soluble N-ethylmaleimide-
sensitive factor attachment protein receptor) complex, implicated
in the fusion of the exocytosis vesicle with the cell plasma mem-
brane. BoNT/B selectively cleaves synaptobrevin 2 (also known
as VAMP2),14 resulting in the inhibition of the acetylcholine
release at the neuromuscular junction, causing a life-threatening
progressive descending flaccid paralysis that requires long term
treatment in intensive care unit.15,16
Botulinum neurotoxin serotypes A and B are increasingly
being used therapeutically to locally paralyse muscles for clinical
or cosmetic benefit. Initially used to treat strabismus in the
1970s, BoNTs have more than a hundred possible medical appli-
cations, including treatment of movement disorders, vascular
cerebral stroke, chronic pain, hyperhidrosis and inflamma-
tion.17,18 Vaccination against botulism is ethically disputable
since it could potentially prevent many patients from the benefit
of these wide therapeutic applications.19
The current treatment against botulism is long, expensive and
difficult to apply on a large scale. It requires respiratory assistance
and the injection of anti-toxin antibodies.20 A human-immuno-
globulin preparation that neutralizes BoNTs (Big-IV, traded as
BabyBIG, supplied by the California Department of Public
Health) was developed from pooled plasma of subjects immu-
nized with a pentavalent vaccine (composed of BoNT/A, B, C,
D and E toxoids) who were selected for their high titres of neu-
tralizing antibodies against BoNT/A and B.21 Because of its
human origin, this immunoglobulin preparation is well tolerated,
but expensive and available in very limited quantity, and thus it is
only used for the treatment of botulism in patients below one
year of age. Considering these limitations, botulism is treated by
injections of horse-derived trivalent (A, B, E) antitoxin (Botulis-
mus–Antitoxin Behring, Novartis, Basel, Switzerland), which is
available in a larger quantity. In March 2013, the Food and
Drug Administration (FDA) approved an Equine heptavalent
botulism antitoxin (HBAT), manufactured by Cangene Corpora-
tion, for the treatment or suspected exposure to Botulinum neu-
rotoxin serotypes A, B, C, D, E, F and G. The animal origin of
these antitoxins increases their immunogenicity and thus the risk
of serum sickness or anaphylaxis.22 To overcome these limita-
tions, recombinant human antibodies that could improve the
safety and tolerance of antitoxin treatment are of particular
interest.
Several studies to date isolated neutralizing antibodies
directed against the HC or LC of BoNTs, starting from an
immune or non-immune human library.23-25 Kalb et al. have
isolated several antibodies targeting the BoNT/B-LC and cross-
interacting with BoNT/B1 and B2 with picomolar affinities
(flow fluorometry evaluation).23 Two of these antibodies, 2B27
and 1B10.1, seemed to inhibit the catalytic activity of some
BoNT/B subtypes by interacting with the LC in vitro, deter-
mined by endopeptidase-MS.23 A human IgG (30B) recogniz-
ing BoNT/B-HC with a high affinity (1.12 10¡12 M) was
previously isolated by hybridoma technology starting from the
lymphocytes of human volunteers vaccinated with the pentava-
lent botulinum toxoid vaccine. This antibody only showed
partial inhibition of BoNT/B1 in vivo as it delayed paralysis,
but did not prevent mice mortality.24 Studies by Kalb et al.
reported in vitro inhibition of the enzymatic activity of different
BoNT/B subtypes using a panel composed of 24 fully human
antibodies directed against BoNT/B1, B2, B3, B4 and B5 toxins
in complex form.23 These IgGs were initially isolated as anti-
body fragments from an immune library and were engineered
to improve their affinity or cross-reactivity, but were not tested
for toxin neutralization properties using in vivo or ex vivo
models, which are required to confirm neutralization.26,27 The
first report of the potentially neutralizing human monoclonal
antibody against BoNT/B, derived from na€ıve single-chain vari-
able fragment (scFv) phage display library against BoNT/B HC
domain was reported by Zhou et al.28 These studies also did
not include in vivo or ex vivo neutralization studies, but relied
exclusively on in vitro cell-based assay. More recent studies by
Garcia-Rodriguez et al. confirmed the neutralizing property of
one human monoclonal antibody (previously reported by
Kalb et al.), 2B18, which recognizes a conserved epitope within
Hn domain on multiple serotypes.29 This antibody, at 25 mg,
fully protected mice exposed to 200 LD50 of BoNT/B1 toxin.
To our knowledge human-like neutralizing antibodies against
BoNT/B toxin targeting its LC have not been published to
date.
This study developed human-like neutralizing antibodies
against BoNT/B by targeting the toxin HC and LC domains.
The recombinant form of the HC and LC of BoNT/B2 were
used to immunize macaques, from which the immune antibody
phage-display library was built. The best scFvs isolated from
each library were selected according to their affinities and cross
reactivity with BoNT/B1. Screening for the best candidates was
performed with holotoxins BoNT/B1 and B2 by assessing inhi-
bition of in vitro endopeptidase activity and neutralization in
the ex vivo mouse phrenic nerve-hemidiaphragm (MPNH) assay
for scFvs targeting LC and HC, respectively. The more stable
form of selected antibodies, expressed as a fusion protein
(scFv-Fc), were further studied for their neutralization proper-
ties in the mouse ex vivo MPNH assay and in vivo mouse
paralysis model.
The study reported here provided an excellent opportunity
to assess the extent of antibody-mediated neutralization of
BoNT/B1 and BoNT/B2 subtypes in ex vivo and in vitro assays
and to confirm in vivo the benefit of synergistic effect of
selected antibodies targeting the HC and LC domains of
BoNT/B.
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Results
Animal immunization and library construction
Non-toxic recombinant BoNT/B2-HC or BoNT/B2-LC were
used to immunize 2 macaques by the immunization schedule
depicted in Figure 1. The same proteins were also used as coating
antigens for ELISA to determine antibody titre in animals, which
increased by 130-fold for B2-HC and 250-fold for B2-LC,
between samples taken just before the first immunization and
just before second immunization, one month later. After
the fourth and last immunization of each animal, a titre of
1/100,000 (BoNT/B2-HC immunization) or 1/300,000
(BoNT/B2-LC immunization) was observed against the immu-
nogen. Both titres were identical to those observed after the third
injection (typically between 3 to 11 d after the third immuniza-
tion) with the same antigen, confirming that a hyper-immune
response had been reached. Figure 1 also indicates the scheme
for bone marrow sampling times post immunization.
For construction of the BoNT/B2-HC library, the RNA from
the macaque bone marrow was transcribed into cDNA and, with
primer sets specific for macaque Fd and VLk DNA regions, the
V-genes were amplified. The amplification increased and reached
an optimum 3 d after the fourth and last immunization when all
primer pairs allowed a stronger amplification compared to other
days. Considering the absence of amplification before the final
immunization, the PCR products amplified at the third day were
considered as specifically encoding variable regions of antibodies
directed against BoNT/B2-HC, thus a hyper-immune response
was raised against the immunogen.30 Two sub-libraries, with a
diversity of 2.6 £ 105and 2.3 £ 105clones coding for Fd and
VLk regions, respectively, were constructed in the pGEM-T
vector. These two sub-libraries were then combined together to
generate a final phage-displayed scFv hyper-immune library com-
posed of 1.1 £ 108 clones in pHAL32 vector, with 95% full size
scFv inserts.
For construction of BoNT/B2-LC library, the V-Gene encod-
ing DNA fragments was similarly amplified starting from the
bone marrow of a second macaque, with the same specific primer
sets.31 The amplification was optimal 7 d after the fourth and
last immunization. All Fd PCR products and all VLk PCR prod-
ucts were separately pooled and inserted into pGEM-T vector.
Two sub-libraries of 5 £ 105 clones for the DNA encoding the
Fd fragment, and 4.65 £ 105 clones for the DNA encoding the
VLk chain, were generated. Starting from these 2 sub-libraries, a
final phage-displayed scFv library, with a diversity of 1.2 £ 108
clones, was constructed in pHAL35 vector, with 93% full-size
scFv inserts.
Panning of the library for the isolation of cross-reacting
scFvs
To isolate scFvs cross-reacting with BoNT/B1 and BoNT/B2
subtypes, the 2 phage-displayed scFv hyper-immune libraries
were subjected to an innovative 2-time panning. First, a 3 round
panning was performed on the BoNT/B1 holotoxin with an
increasing number of washes, then a fourth and last round of
panning was performed against the recombinant chain of the dif-
ferent BoNT/B subtype directly with a high number of washes to
select only the cross-reactive phage at the end of the panning.
For the panning of the hyper-immune library directed against
BoNT/B2-HC (Fig. S1A), the count of phage eluted after the
first round was 4.6 £ 105, decreasing 16-fold after the second
round to 2.84 £ 104, and then increasing 4-fold after the third
round to 1.32 £ 105. After the fourth and last round, the num-
ber of eluted phage increased dramatically by more than a hun-
dred-fold to 1.54 £ 107. To evaluate the cross-reactivity of the
eluted phage, a phage-ELISA was performed with BoNT/B1 and
BoNT/B2-HC as coating antigens. Signals for both antigens
increased progressively and specifically after each round, which
confirms enrichment of scFvs specific for both BoNT/B1 and
BoNT/B2-HC during the course of the panning.
For the panning of the library directed against BoNT/B2-LC,
(Fig. S1B) the number of eluted phage increased from 4.6 £ 105
(first round) to 1.6 £ 108 (third round), which corresponded to
a successful enrichment of phage specific to BoNT/B1 holotoxin.
After the fourth round of panning on BoNT/B2-LC, 1.3 £ 108
phage were eluted which corresponded to the specific enrichment
of phage specific to both BoNT/B1 and B2 subtypes. The cross-
reactivity of the phage eluted after each of the 4 rounds of pan-
ning against BoNT/B1 and BoNT/B2-LC was assessed in
Figure 1. Immunization scheme and bone marrow sampling times. Pro-
tocol for hyperimmunization of cynomolgus macaques (Macaca fascicu-
laris) with BoNT/B2-HC (BHC) and BoNT/B2-LC (BLC). (A): The first 3
injections were administered at one month intervals and the fourth
injection was administered 4 months after the third. Animals were bled
for donation of serum before the first immunization (day 0) and 3 to 5 d
prior to the first booster injection. For BoNT/B2-LC, serum sampling was
also performed 8 days after the third injection and after the last immuni-
zation of each animal. (B): Bone marrow sampling was performed 7 to
11 d prior to the first immunization and at regular intervals after the last
immunization: on days 3, 6, 9, and 14 for BoNT/B2-HC; on days 3, 7, 11,
16, 18 and 23 for BoNT/B2-LC.
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phage-ELISA against both antigens. The reactivity increased after
each round, leading to an optimum reactivity after the fourth
and last round (10- to 13-fold increase of reactivity against
BoNT/B2-LC and BoNT/B1 between the first and last round,
respectively). As expected, after round 2, eluted phage were as
reactive against BoNT/B1 as against BoNT/B2-LC, highlighting
their cross-reacting properties. No reactivity was observed against
keyhole limpet hemocyanin (KLH) or lethal factor (LF), con-
firming their specificity.
Expression and purification of soluble cross-reacting scFvs
targeting BoNT/B-HC or BoNT/B-LC
One hundred clones were randomly handpicked after the
fourth round of panning against BoNT/B2-HC, and then
sequenced to express the non-redundant and non-recombined
scFvs cross-reacting with BoNT/B1 and BoNT/B2. Seventeen
sequences were recombined and thus discarded, and 83 non-
recombined sequences were identified. Among these 83 non-
recombined sequences, only 10 different scFv sequences were
identified: 7 scFvs (B2–1, B2–6, B2–7, B2–11, B2–29, B2–63
and B2–75) were represented once and 3 scFvs (B2–48, B2–86
and B2–119) were represented several times. It is interesting
to note that among the 3 scFvs represented several times, scFv
B2–48 and B2–119 were over-represented, with 43 and 31
occurrences, respectively. The 10 different scFvs were expressed
in E. coli strain HB2151 as soluble scFvs and their affinities were
measured by surface plasmon resonance (SPR). The affinities
ranged from 2.29 nM (B2–6) to 15 nM (B2–63) for the holo-
toxin BoNT/B1 (Table 1), and from 0.2 nM (B2–119) to
11 nM (B2–29) for BoNT/B2-HC, with affinities against
BoNT/B2-HC (the immunogen) always being more favorable
than against BoNT/B1. The affinity of scFv B2–7 was 5 nM and
0.6 nM for the holotoxin BoNT/B1 and BoNT/B-HC, respec-
tively. The Kon (M
¡1 £ s¡1) and Koff (s¡1) values were also cal-
culated for scFv targeting the LC (Table 1), and were most
favorable for BLC3 and BLC42, which were confirmed to bind
to the same or very close epitope on the BoNT/B1 toxin.
After the fourth round of panning of the library directed
against BoNT/B2-LC, 130 clones were randomly picked from
the very high number of eluted phage, and their DNA was
extracted and sequenced. Thirty-one non-recombined and non-
redundant scFv sequences were identified. Twenty-six sequences
(83.87% of the non-recombined, non-redundant sequences)
were found in a single copy, whereas the other 5 sequences
(16.13%) were found in at least 2 copies. The 26 single copy
sequences were expressed as soluble scFvs, purified and their
affinities for BoNT/B1 and BoNT/B2-LC were measured. Affini-
ties for BoNT/B1 ranged from 0.4 nM (BLC3) to 17 nM
(BLC18) (Table 1). Affinities for BoNT/B2-LC were performed
only on a sub-set (50%) of scFvs and they were generally less
favorable than for the holotoxin BoNT/B1, with an affinity of
50 nM determined for BLC3.
Computational analysis
The IMGT/V-QUEST tool was used to analyze the DNA
sequence of the isolated scFv to identify the V, D and J genes
from which they would have derived if they had been of human
origin. For the scFv isolated after the panning of the library
directed against BoNT/B2-HC, 7 occurrences of IGHV4-b*01
were observed, 2 of IGHV3–66*02 and one of IGHV4–4*02,
were observed. These IGHVs were combined with
IGHD1–1*01 (7 occurrences), IGHD3–16*01, IGHD3–3*01
or IGHD5–18*0 (one occurrence each), and with IGHJ5*01,
IGHJ5*02, IGHJ4*02 or IGHJ3*01 (1, 7, 1 and 1 occurrences,
respectively). The genic diversity of the VLk region was slightly
more important as 6 V genes were identified: IGKV1–12*01,
IGKV1–27*01, IGKV1–37*01, IGKV1–17*01, IGKV1–8*01
and IGKV1–39*01 (1, 1, 4, 1, 2 and 1 occurrences, respectively).
Nevertheless, these 6 genes were combined only with IGKJ1*01
or IGKJ4*01 (9 and 1 occurrences, respectively). The percentage
Table 1. Affinities of the scFvs for BoNT/B1 isolated after panning
Sequence Affinity for BoNT/B1 (KD, nM) Kon (1/Ms) Koff (1/s)
BLC3 0.4 7.21 £ 105 2.91 £ 10¡4
BLC4 2.8 4.01 £ 104 1.12 £ 10¡4
BLC6 1.29 4.68 £ 104 6.06 £ 10¡5
BLC7 3 7.96 £ 104 2.45 £ 10¡4
BLC13 9.3 1.4£ 104 1.3£ 10¡4
BLC14 4.15 4.45 £ 104 1.84 £ 10¡4
BLC16 1.68 5.93 £ 104 9.98 £ 10¡5
BLC17 2.3 4.26 £ 104 9.81 £ 10¡5
BLC18 17 7.46 £ 103 1.27 £ 10¡4
BLC19 1.64 6.22 £ 104 1.02 £ 10¡4
BLC28 0.74 1.05 £ 105 8.13 £ 10¡5
BLC29 0.66 1.28 £ 105 8.58 £ 10¡5
BLC30 12.2 — —
BLC33 1.46 1.46 £ 105 2.14 £ 10¡4
BLC42 0.73 2.46 £ 105 1.79 £ 10¡4
BLC43 3.84 4.57 £ 104 1.76£10¡4
BLC44 2.12 8.03 £ 104 1.7£ 10¡4
BLC49 0.648 1.75 £ 105 1.13 £ 10¡4
BLC51 4.9 3.54£104 1.75 £ 10¡4
BLC59 0.524 2.32 £ 105 1.22 £ 10¡4
BLC61 2.39 6.42 £ 104 1.54 £ 10¡4
BLC63 5.98 4.03 £ 104 2.37 £ 10¡4
BLC66 4.6 2.43 £ 104 1.12 £ 10¡4
BLC77 5.3 2.65 £ 104 1.41 £ 10¡4
BLC83 6 4.5£ 104 2.71 £ 10¡4
BLC119 16.5 1.61 £ 104 2.67 £ 10¡4
Sequence Affinity for BoNT/B1 (KD, nM) Kon (1/Ms) Koff (1/s)
B2–1 8.68 5.92 £ 104 5.14 £ 10¡4
B2–6 2.29 — —
B2–7 4.83 2.07£108* —
B2–11 8 — —
B2–29 12 — —
B2–48 8.3 — —
B2–63 14.1 7.11 £ 107* —
B2–75 Non-specific — —
B2–86 6 — —
B2–119 13 — —
*KA (1/M).
— D not determined.
Affinities of the 36 scFvs, 10 isolated after the panning of the libraries
directed against BoNT/B2-HC and 26 against BoNT/B2-LC were measured by
surface Plasmon resonance (Biacore technology) for holotoxin BoNT/B1.
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of similarity between the framework regions of each scFv peptide
sequence and the most similar human germline peptide sequen-
ces (percentage referred to as Germinality Index, GI) was calcu-
lated for each isolated scFv and averaged (average of the antibody
heavy and light chain of the framework regions of each scFv).
For the 10 isolated scFvs, GIs ranged from 80 to 89%, and the
mean GI was 82.7%, which highlights their human-like charac-
ter. The G-score, which evaluates the “humanness,” and also pre-
dicts scFv potential immunogenicity by comparison with human
expressed sequences, was calculated for each VH and VL region
and averaged for each scFv. The scFv mean G-scores for the 10
selected scFvs ranged from ¡0.60 to ¡1.87, with a mean value
equal to ¡1.45 (Table S1).
Similarly, for the library directed against BoNT/B2-LC, scFv
sequences identified after clones-sequencing were subjected to a
computational analysis. As shown in Table 2, low gene diversity
was observed. Indeed, for IGHV genes, only 5 genes from
IGVH3 and IGVH4 were observed with 25 occurrences
of IGHV3–15*01, 2 occurrences of both IGHV3–66*02
and IGHV4-b*02, and finally one occurrence of each of
IGHV4–28*06 and IGHV4-b*01. These 5 VH genes were com-
bined with one of the 28 occurrences of IGHJ4*02 or with
one of the 3 of IGHJ5*02. For antibody light chains, the
use of 3 different IGKV genes (IGKV1, 2 and 3) was
observed: IGKV2–30*02 (25 occurrences), IGKV1–5*03 (2
occurrences) and IGKV1–12*01, IGKV1–8*01, IGKV3–15*01
Table 2. Human germlines gene and Germinality Index (GI) Human germline genes most similar to the genes coding for the 36 selected scFv were retrieved
by IMGT/V-QUEST. The percentage identity between the scFv framework regions and those of the most similar human germline gene sequences (referred to
as Germinality Index, GI) was calculated to indirectly predict their immunogenicity
Heavy chain Light chain GI
scFv V D J V J Heavy chain Light chain Mean
BLC3 IGHV4–28*06 IGHD5–12*01 IGHJ4*02 IGKV1–12*01 IGKJ2*01 85.71 85.71 85.71
BLC4 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*03 87.91 84.26 86.08
BLC6 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*01 85.71 83.14 84.42
BLC7 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*03 85.71 81.81 83.76
BLC13 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*01 82.41 83.14 82.77
BLC14 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*03 84.44 82.02 83.23
BLC16 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*01 85.71 82.02 83.86
BLC17 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*01 84.61 83.14 83.87
BLC18 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*03 85.71 85.22 85.46
BLC19 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*01 86.81 82.02 84.41
BLC28 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*01 86.81 82.02 84.41
BLC29 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*01 84.61 82.02 83.31
BLC30 IGHV3–66*02 IGHD1–1*01 IGHJ5*02 IGKV3–15*01 IGKJ3*01 87.91 66.29 77.1
BLC33 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*01 87.91 79.77 83.84
BLC39 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*01 86.81 72.14 79.47
BLC42 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*01 84.61 82.02 83.31
BLC43 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*03 86.81 82.02 84.41
BLC44 IGHV4-b*01 IGHD5–12*01 IGHJ4*02 IGKV1–5*03 IGKJ2*01 84.61 86.51 85.56
BLC49 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*03 85.71 82.15 83.93
BLC51 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*01 82.41 83.14 82.77
BLC59 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*01 84.61 80.89 82.75
BLC61 IGHV4-b*02 IGHD2–8*02 IGHJ5*02 IGKV1–8*01 IGKJ1*01 82.41 82.55 82.48
BLC63 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*01 75.82 79.77 77.79
BLC66 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*03 87.91 84.09 86
BLC77 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ1*01 86.81 85.39 86.1
BLC80 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*03 85.71 80.68 83.19
BLC83 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*01 84.61 82.02 83.31
BLC88 IGHV4–4*02 IGHD4–17*01 IGHJ4*02 IGKV1–5*03 IGKJ2*01 85.71 84.26 84.98
BLC90 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*01 86.81 82.02 84.41
BLC99 IGHV3–66*02 IGHD1–1*01 IGHJ5*02 IGKV1–17*01 IGKJ3*01 84.61 87.05 85.83
BLC119 IGHV3–15*01 IGHD5–12*01 IGHJ4*02 IGKV2–30*02 IGKJ2*01 85.71 82.02 83.86
B2–1 IGHV4-b*01 IGHD1–1*01 IGHJ5*02 IGKV1–37*01 IGKJ4*01 85.71 78.4 82.06
B2–6 IGHV4-b*01 IGHD1–1*01 IGHJ5*02 IGKV1–37*01 IGKJ4*01 85.71 76.13 80.92
B2–7 IGHV4-b*01 IGHD1–1*01 IGHJ5*02 IGKV1–37*01 IGKJ4*01 85.71 77.27 81.49
B2–11 IGHV3–66*02 IGHD3–16*01 IGHJ5*01 IGKV1–12*01 IGKJ1*01 86.81 90.9 88.85
B2–29 IGHV4-b*01 IGHD1–1*01 IGHJ5*02 IGKV1–27*01 IGKJ4*01 89.01 86.36 87.68
B2–48 IGHV4-b*01 IGHD1–1*01 IGHJ5*02 IGKV1–37*01 IGKJ4*01 85.71 77.27 81.49
B2–63 IGHV4–4*02 IGHD3–3*01 IGHJ4*02 IGKV1–17*01 IGKJ4*01 91.2 87.64 89.42
B2–75 IGHV3–66*02 IGHD5–18*01 IGHJ3*01 IGKV1–39*01 IGKJ4*01 81.31 82.95 82.13
B2–86 IGHV4-b*01 IGHD1–1*01 IGHJ5*02 IGKV1–8*01 IGKJ4*01 85.71 77.27 81.49
B2–119 IGHV4-b*01 IGHD1–1*01 IGHJ5*02 IGKV1–8*01 IGKJ4*01 85.71 77.27 81.49
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and IGKV1–17*01 (1 occurrence each). These IGKV
genes are also combined to 4 different IGKJ (of IGK
families 1, 2 and 3). For the antibody heavy chain, 25
associations “IGHV3–15*01/IGHD5–12*01/IGHJ4*02”were
observed and were principally associated with one of the 17
“IGKV2–30*02/IGKJ2*01” combinations. Even with apparent
low diversity, the GI score assessments revealed the presence of
several point-mutations, thus increasing the sequence diversity.
The GIs of the 26 isolated scFvs are presented in Table 2, with
values ranging from 75.82% to 87.91% for the antibody heavy
chains and from 79.77% to 84.09% for antibody light chains,
resulting in an average value for the whole scFv molecule of
between 77.79% and 86% (Table 1). The mean G-scores for 26
selected scFvs ranged between ¡1.0035 and¡2.746, underlining
that some scFvs are close to human antibody sequences
(Table S1).
Differential dose response curves of BoNT/B1 and BoNT/B2
subtypes in ex vivo and in vitro assays
In order to select potentially cross-neutralizing scFvs directed
against the BoNT/B2-LC or HC, during screening studies we
applied the in vitro endopeptidase assay or the ex vivo MPNH
assay using both BoNT/B1 and BoNT/B2 subtypes.
For the in vitro endopeptidase assay, dose response curves were
compared for complex forms of BoNT/B1 and BoNT/B2 and for
pure holotoxin BoNT/B1. Interestingly, complex BoNT/B2 sub-
type exhibited at least 2,000-fold higher enzyme activity in this
model compared to complex BoNT/B1 (Fig. S2), despite compa-
rable activities in the mouse LD50 and paralysis in vivo assays.
Additional studies with purified LC of BoNT/B1 and BoNT/B2
did not show a difference in enzyme activity, suggesting that
complex BoNT/B2 toxin may be more stable in this assay com-
pared to BoNT/B1 toxin.
The complex form of BoNT/B1 had »4 times higher endo-
peptidase activity relative to pure BoNT/B1 toxin (Fig. S2),
which was also confirmed in vivo when the 2 preparations were
tested together in the paralysis assay. Such differences are often
observed for preparations calibrated in different laboratories and
are not unexpected.
A full dose range for pure BoNT/B1 subtype (60 LD50.mL
¡1
to 240 LD50.mL
¡1) has been previously assessed using in-bred
Balb/c mice in the ex vivo MPNH assay.32 A similar dose
response curve could not be established with complex BoNT/B2
because there was no significant dose effect above
50 LD50.mL
¡1, and a very steep dose-effect at lower concentra-
tions, which prevented similar fitting. However, complex
BoNT/B2 was found to be 500-fold more potent relative to pure
BoNT/B1 in the MPNH assay since 0.2 LD50.mL
¡1 of complex
BoNT/B2 induced similar paralysis to 100 LD50 of pure
BoNT/B1. The much greater paralytic effect of complex
BoNT/B2 was initially evidenced from a 50% paralysis time that
was 3-times shorter with 200 LD50.mL
¡1 of BoNT/B2 complex
than with 240 LD50.mL
¡1 of pure BoNT/B1 (Fig. 2). To
further study the exacerbated activity of BoNT/B2 subtype,
human neuronal cells (SH-SY5Y), differentiated as previously
described,33 were exposed to different doses of subtypes and nor-
adrenaline release levels assessed after 48 h. Complex BoNT/B2
was found to be at least 30 times more potent than pure
BoNT/B1 in this neuronal cell model (data not shown).
Since BoNT/B2 toxin was confirmed to be relatively more
potent in several in vitro and ex vivo models, these studies high-
light the assay specific differences between serotypes and subtypes
of toxin and the need for determination of
optimum doses in each assay system.
In vitro endopeptidase inhibition
properties of scFvs and scFv-Fcs directed
against BoNT/B-LC
Initial screening of the 26 isolated
scFvs was performed with the BoNT/B2
subtype in the endopeptidase assay
because BoNT/B2-LC was used for the
immunization. Six scFvs were identified as
having some inhibitory properties against
this subtype. ScFv BLC3 and BLC42
were selected for further studies because
a quantity of »2 mg inhibited 50%
of the enzyme activity induced
by 0.2 LD50 of complex BoNT/B2
(Fig. 3A). When a more stable version of
this clone (scFv-Fc) was used in the same
assay, 50% inhibition of the same dose of
toxin was observed at 0.001 mg, repre-
senting some 2000-fold increase in
the inhibition ratio. However, as in
previous studies with scFv-Fcs against
BoNT/A-LC,31 high background
Figure 2. Dose response curves of BoNT/B1 and BoNT/B2 subtypes in ex vivo MPNH. Dose response
curves for complex BoNT/B1, complex BoNT/B2, and pure BoNT/B1 were generated in MPNH on tis-
sues taken from in-bred Balb/c mice. Time to 50% paralysis was calculated by linear regression of
each individual twitch response curve. Each point is the mean § SEM of 3 to 6 hemidiaphragm
preparations except for complex BoNT/B1, which was from a single hemidiaphragm preparation.
Where no error bar is visible, it is concealed by the symbol.
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prevented analysis of the full dose
response (data not shown).
All 26 clones were also tested
for their ability to inhibit pure
BoNT/B1 endopeptidase activity,
initially with 70 LD50 and subse-
quently with 30 LD50, using the
same initial protein concentration
of 10 mg.mL¡1 for each clone.
Only two scFvs (BLC3 and
BLC42) also inhibited BoNT/B1
subtype, with scFv BLC3
showing 50% inhibition of
30 LD50.mL
¡1 (150 pg.mL¡1) at
»0.5–1.0 mg.mL¡1 (molar ratio
»20,000:1 for scFv:toxin). The
scFv BLC3 was selected for further
inhibition studies because BLC3 and BLC42 were confirmed to
compete for the same epitope on BoNT/B1 and the affinity of
BLC3 for BoNT/B1 was slightly higher compared to BLC42.
The inhibition properties of scFv BLC3 was further confirmed
using complex form of BoNT/B1 at 10 LD50.mL
¡1 where 50%
inhibition was seen at »2–3 mg.mL¡1 (Fig. 3B), confirming
cross-inhibition property of BLC3. At an equivalent range
of concentrations, scFvs to BoNT/A-LC did not inhibit endo-
peptidase activity of either BoNT/B1 or B2 subtype. Assay speci-
ficity was confirmed with polyclonal antibody to BoNT/B
serotype.
Ex vivo neutralization properties of scFvs and scFv-Fc
directed against BoNT/B-LC and -HC
The scFvs BLC3 and BLC42 were also tested in the ex vivo
MPNH assay, but their neutralization capacities were found to
be weak (data not shown). The use
of a potentially more stable version
of the BLC3 (scFv-Fc) resulted in
much stronger neutralization of
pure BoNT/B1 (100 LD50.mL
¡1)
and of complex BoNT/B2
(0.2 LD50.mL
¡1) (Fig. 4A
and 4B). At 2mg.mL¡1, BLC3
increased 50% paralysis time for
BoNT/B2 by 147 minutes and
for BoNT/B1 by 56 minutes,
resulting in 38% and 26% inhi-
bition of toxin-induced paralysis,
respectively (Table 3a and 3b).
Neutralization of BoNT/B2
subtype, but not of BoNT/B1,
by scFv BLC3 was better than
that for the commercial polyva-
lent F(ab)2 antitoxin, at
20 mIU.mL¡1, which increased
50% paralysis time by about
100 min for both subtypes
(Fig. 4A and 4B).
Initial screening of all the anti-BHC scFvs in the MPNH assay
identified 6 scFvs (>50%) with some inhibitory properties
against BoNT/B1 (100 LD50.mL
¡1), with scFv B2–7 showing
the strongest neutralization at 29 mg.mL¡1, which was compara-
ble to that observed with commercial polyvalent F(ab)2 antitoxin
at 20 mIU.mL¡1. B2–7 was thus selected for further characteri-
zation against 0.2 LD50.mL
¡1 of complex BoNT/B2 (equipotent
paralytic dose to 100 LD50.mL
¡1 of pure BoNT/B1). Dose
response for neutralization of complex BoNT/B2 by scFv B2–7
(dose range between 0.1 and 9.85 mg mL¡1) showed a 52 min
delay in the 50% paralysis time, representing 23% inhibition at
5.0 mg, which increased to a 374 min delay and 73% inhibition
at 10 mg of scFv B2–7 (supplementary data Fig. 3 and supple-
mentary data Table 2).
Further characterization studies of B2–7 against
100 LD50.mL
¡1 of pure BoNT/B1 were performed using the
Figure 3. Endopeptidase inhibition activity of scFvs targeting BoNT/B-LC. Endopeptidase activity on 35
amino acid VAMP2 peptide substrate (VAMP2 60–94) by complex BoNT/B2 (0.2 LD50mL
¡1). (A) and complex
BoNT/B1 (10 LD50.mL
¡1) (B), was inhibited dose dependently by selected scFvs targeting BoNT/B-LC. Dou-
bling dilutions of scFv BLC3 and BLC42 were used from 10 to 0.01 mg.mL¡1. scFvs against BoNT/A1-LC49
were included as negative controls. Polyclonal antibody to BoNT/B was used as a positive control. Each
point is a mean of triplicate determinants within the same experiment with § SEM for error bars. Data is
representative of at least 3 independent experiments. Where no error bar is visible, it is concealed by the
symbol.
Figure 4. Neutralization activity in MPNH of scFv-Fc BLC3 targeting BoNT/B-LC. Neutralization of 100
LD50mL
¡1 of pure BoNT/B1 (A) and 0.2 LD50.mL¡1 of complex BoNT/B2 (B) by scFv-Fc BLC3 at 2 mg.mL¡1,
was studied in the MPNH assay. Paralysis of the tissue induced by the toxin alone is indicated in red. Dotted
line indicates 50% paralysis. Antibody neutralization results in prolongation of the 50% paralysis for the
same dose of toxin. In neutralization experiments (blue), each data point is a mean of 3 separate hemidiaph-
ragm preparations with error bar § SEM. Commercial equine F(ab’)2 polyclonal serum was used as a positive
control at 20 mIU.mL¡1 (green). Control tissues were not exposed to the toxin (gray).
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scFv-Fc form of B2–7. These neutralization studies in MPNH
using lower dilutions of B2–7 showed significant neutralization
of pure BoNT/B1 toxin between 1.0 to 5.0 mg.mL¡1, with the
minimum neutralizing capacity at »0.1 mg.mL¡1. The 50%
paralysis time was delayed by 27 min at 0.1 mg.mL¡1 and
67 min at 1.0 mg.mL¡1 respectively, representing 21% to 28%
neutralizing capacity (Fig. 5A, Table 4a). Due to the non-spe-
cific effect of this antibody at doses exceeding 5 mg.mL¡1, it was
not possible to assess neutralization at higher doses of B2–7 in
the scFv-Fc form.
Final neutralization studies were performed using the scFv-Fc
form of B2–7 antibody (dose range 1.0 to 30 mg.mL¡1) against
the BoNT/B2 subtype. Significant neutralization of complex
BoNT/B2 was obtained at 10–30 mg.mL¡1, with the minimum
neutralizing capacity below 1.0 mg.mL¡1. The prolongation of
paralysis time ranged from 30 to 80 min, with 28% neutraliza-
tion obtained at 30 mg.mL¡1 (Fig. 5B, Table 4b).
The neutralization dose response for scFv and scFv-Fc B2–7
was not different, and both preparations showed similar inhibi-
tions of »26–28% over a 5- to 10-fold change in antibody dose
(Table 4a and 4b).
In vivo neutralization of scFv-Fc against BoNT/B-HC
and -LC
The scFv-Fc forms of BLC3 and B2–7, targeting BoNT/B-LC
and HC, respectively, were tested in vivo both individually, and
in combination for a synergistic neutralizing effect, in the mouse
flaccid paralysis protection model against complex BoNT/B2
(0.2 LD50 per dose). Complete protection was achieved with 25
and 2.5 mg of BLC3, whereas B2–7 did not fully protect mice, at
25 mg per dose, but lowered the intensity of paralysis with no
clear dose response. Results were comparable at 24 h and 48 h
observations (Fig. 6A and 6B). Additional neutralization studies
with higher concentrations (50 mg and 100 mg) of scFv B2–7
demonstrated a similar effect with no benefit of dose increase.
However, the combination of BLC3 and B2–7 fully protected
mice in vivo where protection was not observed by each antibody
alone (0.25 mg of each antibody) (Fig. 6A and 6B), confirming
effective synergistic effect.
Discussion
The aim of this project was to develop antibody fragments
cross-neutralizing BoNT/B1 and BoNT/B2 subtypes based on
the panning of a phage-displayed library using recombinant
forms of HC and LC of BoNT/B2
toxin. The C-termini of BoNT/B1
and BoNT/B2 heavy chains
(BoNT/B1-HC and BoNT/B2-HC)
were targeted because this region
is known to harbour neutralizing
epitopes.34,35 The recombinant
form of BoNT/B2-LC was also
used because previous studies have
confirmed that antibodies specific
to BoNT/A-LC can inhibit
enzyme activity and fully protect
mice from toxin challenge.36 Mac-
aques (Macaca fascicularis) were
used for immunization with
recombinant non-toxic antigens
because antibodies derived
from this species present a
human-like character favorable for
future therapeutic applica-
tions,37,38 and for ethical concerns
because immunization of human
volunteers with potential bio-war-
fare agents such as BoNT is
not conceivable. In addition, na€ıve
Table 3a. Neutralization of pure BoNT/ B1 (100 LD50.mL
¡1) by scFv-Fc BLC3
in the mouse phrenic nerve-hemidiaphragm assay
scFv-Fc-BLC3
(mg.mL¡1)
50% Paralysis time
(min) (mean, n D 3)
Prolongation time
(min) (mean, n D 3)
% Inhibition
(mean, n D 3)
2.0 169 56 26.0
Control (no toxin) 647 100
Figure 5. Neutralization activity in MPNH of scFv-Fc B2–7 targeting BoNT/B-HC. Dose dependent neutraliza-
tion of pure BoNT/B1 (100 LD50.mL
¡1) (A) and complex BoNT/B2 toxin (0.2 LD50.mL¡1) (B) by scFv-Fc B2–7,
was studied in MPNH at concentrations between 30 and 0.1 mg.mL¡1. Paralysis of the tissue induced by the
toxin alone is indicated in red. Dotted line indicates 50% paralysis. Antibody neutralization results in pro-
longation of the 50% paralysis for the same dose of toxin. Each neutralization set is from a single hemidiaph-
ragm preparation per concentration. A commercial trivalent equine F(ab’)2 polyclonal serum was used as
positive control (green). Control tissues were not exposed to the toxin (gray).
Table 3b. Neutraliszation of complex BoNT/B2 (0.2 LD50.mL
¡1) by scFv-Fc
BLC3 in the mouse phrenic nerve-hemidiaphragm assay
scFv-Fc BLC3
(mg.mL¡1)
50% Paralysis time
(min)(mean, n D 3)
Prolongation time
(min)(mean, n D 3)
% Inhibition
(mean, n D 3)
2.0 247 147 38.1
Control (no toxin) 647 100
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libraries without affinity maturation have resulted in low neu-
tralization capacities.24 This animal model allows the injection
of the antigen in the presence of a strong adjuvant that induces
a hyper-immune response, and thus the isolation of high-affinity
antibody fragments.39-41
To limit the number of recombinant antibodies for clinical
development for the neutralization of the BoNT/B serotype, it is
desirable to isolate antibodies that cross-react with BoNT/B1 and
BoNT/B2, similar to the antibody C25 developed previously for
the neutralization of BoNT/A1 and BoNT/A2 subtypes.
42
Murine antibody C25 directed against BoNT/A1-HC was later
humanized (HuC25) to enable therapeutic use. This antibody
was engineered to enhance its cross-reactivity with BoNT/A2,
resulting in a mutant variant (CR2) with improved affinity to
BoNT/A2 (from 109 nM to 87 pM), while retaining its affinity
to BoNT/A1 (115 pM). It was later shown that CR2 had the
same capacity to inhibit the enzymatic activity of BoNT/A1 and
BoNT/A2.43
We hypothesized the possible isolation of a cross-neutralizing
antibody from an immune NHP library without in vitro engi-
neering, contrary to other publications.42,43 The high percentage
of identity (96%) between BoNT/B1 and BoNT/B2 subtypes
also increases the probability of cross-neutralization. Because of
BoNT/B toxicity, previous studies aimed at isolating neutralizing
or detecting antibodies by targeting their non-toxic recombinant
HC or LC domains. The production of antibodies that inhibit
BoNT/B enzyme activity by targeting its LC have been reported
and emphasize the presence of potentially protective epitopes in
its sequence.23,44 However, there is no published study to date
describing antibodies targeting the BoNT/B-LC that also neu-
tralize toxin activity in vivo. Antibodies simultaneously inhibiting
in vitro catalytic activity of BoNT/B1 and B2 in the same range
were noted by Kalb et al.23 Nevertheless, as confirmed in the case
of BoNT/A studies, to efficiently neutralise the toxin, scFvs need
to be used in combination or undergo affinity maturation to
improve their affinity.24,45-47 Consequently, the same result
should be expected for BoNT/B.
To isolate scFvs potentially neutralizing both BoNT/B1 and
BoNT/B2, the 2 hyper-immune libraries were screened using a
2-step panning process. As BoNT/B1 holotoxin, BoNT/B2-HC
and BoNT/B2-LC fragments were available for the study, our
choice was to immunize with the recombinant BoNT/B2 non-
toxic fragments (BoNT/B2-HC and BoNT/B2-LC) in order to
focus the library on a region known to harbour neutralizing
epitopes. The panning was then initiated with the holotoxin
BoNT/B1 in order to select scFvs reacting with fully active toxin,
which is also derived from a different subtype to the immunogen.
This approach was validated because the number of eluted phage
was comparable to that reported in previous studies,39 and 26
(sub-) nanomolar scFvs targeting BoNT/B2-LC and 10 (sub-)
nanomolar scFvs targeting BoNT/B2-HC were finally isolated.
After the third immunization with BoNT/B2-HC, the ELISA
titre reached 1/100,000, with no further increase, indicating that
the macaque had been hyper-immunized. Five days prior to the
fourth injection, to control the evolution of the immune
response, specific primer sets that specifically amplified the DNA
coding for VH and VL antibody regions were used. No DNA
coding for antibody fragments were amplified using primers spe-
cific for the amplification of VH or VLk regions. After the last
injection, bone marrow was iteratively sampled and optimal
amplification of DNA coding VH and VL observed 3 d after the
final boost. Because of the absence of amplification prior to the
final immunization, the DNA amplified after the last immuniza-
tion was regarded as specifically encoding variable regions react-
ing with the antigen. Due to the hyper-immune nature of the
animal response, the timely PCR amplification, and according to
our previous observations and definitions, the phage-displayed
library built from this DNA was regarded as a hyper-immune
library.48 The phage-ELISA study confirmed the specificity of
eluted phage for both BoNT/B1 and BoNT/B2-HC. The strong
increase in the number of phage isolated after panning with
BoNT/B2-HC was no surprise, as the panning was performed
using the same molecule previously chosen for immunization.
Nevertheless, among one hundred clones eluted from the pan-
ning randomly picked and sequenced, only 10 non-recombined
and non-redundant scFvs were identified, which was lower than
in some of our previous studies.31,39 It may be noted that the 2
scFvs (B2–48 and B2–119) constituting the vast majority of the
100 sequenced scFvs (43 and 31 occurrences, respectively) pre-
sented the best affinities for BoNT/B2-HC among those
observed, which may explain their high frequency. From these
10 different scFvs, 9 presented nanomolar or sub-nanomolar
affinities for both BoNT/B1 and BoNT/B2-HC, with affinities
for BoNT/B2-HC (from 0.2 nM to 11 nM) always being more
favorable, probably as a consequence of its use as an immunogen.
The neutralization capacities of the scFvs, targeting the HC,
against BoNT/B1 and BoNT/B2 subtypes were evaluated in the
ex vivo hemidiaphragm assay, which has been shown to correlate
well with the mouse in vivo assay for assessments of the neutraliz-
ing activity of polyclonal antibodies against toxin serotypes A, B
Table 4a. Dose dependent neutralization of pure BoNT/B1 (100 LD50.mL
¡1)
by scFv-Fc B2–7 in the mouse phrenic nerve-hemidiaphragm assay
scFv-Fc B2–7
(mg.mL¡1)
50% Paralysis time
(min)
Prolongation
time (min)
%
Inhibition
0.1 140 27 21.6
0.5 165 52 25.5
1.0 180 67 27.8
5.0 170 57 26.3
Control(no toxin) 647 100
Table 4b. Dose dependent neutralization of complex BoNT/B2 (0.2 LD50.
mL¡1) by scFv-Fc B2–7 in the mouse phrenic nerve-hemidiaphragm assay
scFv-Fc B2–7
(mg.mL¡1)
50%Paralysis
time (min)
Prolongation
time (min)
%
Inhibition
1.0 130 30 20.1
5.0 170 70 26.3
10 160 60 24.7
30 180 80 27.8
Control(no toxin) 647 100
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and E.26 The best scFv candidate was B2–7, which significantly
delayed the time to 50% paralysis induced by both BoNT/B1
and BoNT/B2 at 29 mg.mL¡1 and 10 mg.mL¡1, respectively.
Strong neutralization was also confirmed with the scFv-Fc fusion
form of the B2–7 against the same concentrations of BoNT/B1
and BoNT/B2 subtypes, inducing a 67 min and 80 min pro-
longation of the 50% paralysis time at 1.0 and 30 mg.mL¡1,
respectively. This antibody is the most promising candidate for
further development from the panel studied, targeting the HC of
BoNT/B. Although the affinity of B2–7 antibody for
BoNT/B2-HC was higher (0.6 nM) in comparison to affinity
for holotoxin BoNT/B1 (5 nM), neutralization in the ex vivo
assay indicated 8% higher neutralization of BoNT/B1 at 1.0 mg.
However, a narrow range (between 20–28%) of the inhibition
profile was observed across the 50- to 30-fold change of concen-
tration for both subtypes. Considering the mechanism of action
of the toxin, the scFvs targeting BoNT/B-HC should inhibit the
adhesion to the cell surface or the penetration into the cytosol by
steric hindrance, but scFv or even scFv-Fc fragment of a single
antibody may not protect from toxin challenge in vivo. This was
confirmed in the mouse in vivo protection assay, where scFv-Fc
B2–7 lowered the severity, but failed to fully protect the mice
from BoNT/B2 toxin-induced paralysis, with no dose benefit.
These results are comparable to those in the ex vivo MPNH neu-
tralization assay, where prolongation time and 50% inhibition of
paralysis of B2–7 was similar over a 10-fold range in dose. Bio-
chemical characterization of B2–7 binding was not part of this
study, but preliminary data suggests that this may not be an effec-
tive blocking antibody, thus explaining poor dose effect in neu-
tralization studies. Neutralizing antibodies targeting only the
BoNT/A-HC domains have been previously reported,48 and
their efficacy in vivo is considered to be increased by increasing
the size of the fragment or including combinations.47-49 Com-
bining antibodies targeting both HC and LC to also achieve high
protection in vivo was of interest.
In order to select scFvs target-
ing BoNT/B-LC that bind
and neutralize BoNT/B1 and
BoNT/B2, we applied the same
strategy as for selection of anti-
bodies targeting the BoNT/B-HC.
The immunization of one monkey
with 4 injections of the non-toxic
BoNT/B2-LC led to a titre supe-
rior to 1/300,000 for BoNT/B2.
Before the final immunization, no
amplification of any VH or VL
DNA was detected, thus it can be
deduced that the amplification
observed after the last boost corre-
sponds to neo-synthesized anti-
bodies specifically directed against
the immunogen, BoNT/B2-LC.
Starting from the amplicons
obtained 11 d after the final boost,
where the retro-amplification of
VH and VL RNA was optimal, the hyper-immune library was
generated in the pHAL35 vector. The increasing reactivity against
both BoNT/B1 and BoNT/B2-LC observed after each round of
panning emphasized the cross-binding properties of eluted phage.
Considering these results, clones eluted after the fourth round of
panning should present high affinity against both subtypes, and
were thus used for further investigations. From the 26 different
scFvs, 25 presented nanomolar affinities, of which 3 had
sub-nanomolar affinities for BoNT/B1, with the highest
affinity observed for BLC3 (0.4 nM) with favorable
Kon and Koff values. In contrast to results with scFvs targeting
BoNT/B-HC, affinities for BoNT/B2-LC, which was an immu-
nogen, were less favorable, and were in the range of
38–280 nM, which could represent better binding of this
antibody to the whole active toxin.
Because of their low nanomolar affinities, the 26 scFvs
were assessed for their inhibition properties in the VAMP2
endopeptidase assay. Six (23%) scFvs inhibited the catalytic
activity of 0.2 LD50.mL
¡1 complex BoNT/B2, and only 2 of
these (7.6%) also inhibited 30 LD50.mL
¡1 of pure BoNT/B1
subtype. The inhibition of BoNT/B1 and BoNT/B2 catalytic
activity observed for all scFvs was dose-dependent between
0.1 and 10 mg.mL¡1. The inhibition of endopeptidase activ-
ity was considerably improved when using potentially more
stable scFv-Fc bivalent format of an antibody that is similar
to IgG. This observation was consistent with our previously
published studies with antibodies targeting BoNT/A-LC
where a reduced inhibition ratio in comparison to scFv
format was noted. In Chahboun et al., we reported in vitro
inhibition property for scFv 2H8 targeting the BoNT/A-LC
with a molar ratio of 64,000:1 (scFv:toxin).31 In Miethe
et al., inhibition was observed at a molar ratio of 6,500:1 for
scFv-Fc 2H8 (scFv-Fc:toxin).50 Furthermore, we observed
similar results for antibody targeting the BoNT/E-LC
(Miethe et al., submitted). The improved stability, and
Figure 6. Neutralization activity of scFv-Fc BLC3 and B2–7 in vivo. The neutralization activity of scFv-Fc BLC3
and B2–7 was determined in mouse paralysis assay in vivo after 24 h (A) and 48 h (B). Complex BoNT/B2
toxin (0.2 LD50 per dose) was pre-mixed with each antibody at 0.25 mg, 2.5 mg and 25 mg per dose. When
tested in combination, 0.25 mg of each of BLC3 and B2–7 were mixed with the same dose of complex BoNT/
B2 toxin. Antibody:toxin mixtures were left for 30 min at room temperature before injecting subcutaneously
0.1 ml into left inguinocrural region of female MF1 strain of mice. Animals were scored at 24 and 48 h post
injection. Results are expressed as mean score of 4 mice § SEM. Positive control group of mice were injected
with BoNT/B2 toxin alone, and negative control group were given the maximum concentration of antibody
in the absence of toxin.
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apparent increase in affinity and steric hindrance improve
IC50 values as well as the molar ratio after converting the
scFv to either scFv-Fc or IgG. This is the reason why short
chain scFv with in vitro inhibition properties will not neces-
sarily protect in vivo. We observed this with all neutralizing
antibodies targeting the LC of the toxin suggesting that the
role of steric hindrance in neutralization is particularly rele-
vant for antibodies targeting this domain. Use of scFv-Fc also
increased the backgrounds at higher antibody concentration,
which was also observed in the previous study.50 It was con-
firmed that substrate size in the endopeptidase assay is not a
contributing factor by using a larger 50 amino acid human
VAMP2 peptide (VAMP2 45 to 93 sequences, including a
C-terminal Cysteine residue) as a substrate, with comparable
inhibition results. Furthermore, it was confirmed that BLC3
is of interest as a potentially neutralizing antibody for further
development by performing the neutralization study in the
MPNH as scFv-Fc to gain avidity. The scFv-Fc BLC3 neu-
tralized paralysis and increased the 50% paralysis time by
56 min and by 147 min for BoNT/B1 and BoNT/B2,
respectively. Neutralization of BoNT/B2 with 2 mg of
scFv-Fc BLC3 was superior to neutralization with the com-
mercial polyvalent F(ab)2 antibody at 20 mIU. However, it
should be emphasized that it is not possible to directly
extrapolate this information to likely protection in vivo in
comparison to current products, which are hyper immune
horse antitoxin or human IgG. Here, scFvs appear to be
more protective against BoNT/B2 than for the BoNT/B1
subtype, which was only used during the panning process.
Recombinant antibodies that inhibit the catalytic activity
of BoNT/B by targeting its LC have been isolated after affin-
ity maturation process, demonstrating comparable in vitro
inhibition properties.23 The inhibition of endopeptidase
activity by antibodies directed against BoNT/B-LC is thought
to mainly depend on their direct interaction with toxin, ini-
tially outside of the cells, but persisting within, and prevent-
ing the translocation of the toxin LC from the endosome to
the cytosol by steric hindrance. Re-formatting the neutralizing
antibody in order to facilitate its cell entry, without prerequi-
site interaction with the toxin, could allow neutralization
after a longer delay post-intoxication and offer a longer win-
dow of opportunity in therapy. Consequently, the develop-
ment of such monoclonal antibodies is of great interest due
to their high specificity for toxin serotype. To our knowledge,
neutralizing human-like monoclonal antibodies against
BoNT/B -LC that also protect in vivo have not been pub-
lished to date. Our studies demonstrated that scFv-Fc BLC3
at doses as low as 2.5 mg fully protected mice from paralysis
induced by 0.2 LD50 of BoNT/B2 toxin. Whereas it is not
possible to directly compare with other protection studies,
which always use IgG, human monoclonal antibody targeting
BoNT/A-LC at 100 mg dose fully protected mice from
25 LD50,
36 which is in a similar range as reported
here. BLC3 demonstrated an affinity to the holotoxin
BoNT/B1 that was over 100-fold higher than to the
non-toxic immunogen, BoNT/B2-LC, which also suggests a
preference to conformational epitopes on the whole toxin,
and in turn may also contribute to its higher potency in
vivo. That high affinity of short chain antibody fragments is
important for in vivo efficacy has been reported for antibod-
ies against BoNT/A-HC and LC.49
Several studies have confirmed synergistic effect when 2 or
more antibodies are combined together to increase the neutraliz-
ing potency.47-49 When the scFv-Fc B2–7 (targeting HC) and
BLC3 (targeting LC) were combined, they fully protected mice
in vivo at a dose where each antibody alone only decreased the
symptoms of paralysis, without fully protecting, confirming
effective synergistic effect.
The hyper-immune libraries generated during this study were
obtained starting from a non-human primate. Even though they
are close to their human counterpart, macaque IgGs are not iden-
tical and could induce a human-anti-macaque-antibody
response.31 This anti-antibody response leads to a decrease in effi-
cacy of therapeutic antibodies due to their fast elimination from
the bloodstream. A computational analysis was performed to pre-
dict the immunogenicity of isolated scFvs using 2 parameters:
the GI and the G-score.51 The GI allows the determination of
the identity percentage between the scFv framework sequences
and those of their closest germline human counterparts identified
with the IMGT/DomainGapAlign tool. Because the germline
sequences naturally code for human antibodies, they were consid-
ered as non-immunogenic. The closer a sequence is to germline,
the more likely it is to be well tolerated.52 The GI of B2–7, the
most neutralizing scFv targeting the BoNT/B-HC, was found to
be 80.5%, thus emphasizing the human-like quality of this anti-
body, but the value was lower than the average for human IgGs
(about 95%51). The GI for BLC3, the most promising neutraliz-
ing antibody targeting BoNT/B-LC, presents an identity of
86.68% (87.64% for its heavy chain and 85.71% for its light
chain), indicating that it should be well tolerated during thera-
peutic use.
To improve the tolerance of B2–7 and BLC3, these scFv can
be subject to hyper-humanization process.30,52,53 The process of
humanization consists of the replacement of framework regions
(humanization), or even complementarity-determining regions
(hyper-humanization) of amino acids that are different between
the scFvs and the closest human germline antibody sequence.
Amino acids diverging from the human germline sequence are
replaced with the amino acid present at the same position in the
germline sequence. Introduction of such mutations could affect
stability, and thus affinity. Such an approach was already success-
fully applied to the anti-anthrax toxin antibody, Fab35 PA83,
53
whereby germline humanization increased the GI index from
87% to 97%.
In conclusion, these results highlight the success of our
strategy based on targeting the HC and LC domain of the
toxin and the use of NHP hyper-immune libraries. Such a
library was successfully screened here by panning using 2
antigens (BoNT/B1 and BoNT/B2-HC or BoNT/B2-LC).
Furthermore, we applied relevant in vitro and ex vivo meth-
ods during the screening process to isolate scFvs B2–7 and
BLC3 targeting BoNT/B HC and LC respectively. These two
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scFvs cross-reacted and neutralized the 2 main subtypes
of BoNT/B, BoNT/B1 and BoNT/B2, in ex vivo MPNH.
Furthermore, when combined, these antibodies exhibited
potent synergistic protection in vivo when studied in scFv-Fc
format. The framework regions of B2–7 and BLC3 were
close to the human germline sequences, predicting a good
tolerance for clinical use, but their tolerance could be further
increased by germline-humanization. The approach presented
here is certainly of broad interest, in particular to isolate
recombinant antibodies targeting infectious agents.
Material and Methods
Toxins and antitoxins
Botulinum B1 and B2 complex toxins were prepared by Insti-
tut Pasteur (Paris, France) as previously described,54,55 and activ-
ity determined as 2 £ 107 LD50.mL¡1, (3.6 mg.mL¡1 total
protein from proteolytic strain C. botulinum B1 strain # 7273,
batch 02) and 2 £ 105 LD50.mL¡1 (2.9 mg.mL¡1 total protein
from proteolytic strain C. botulinum B2 strain # BL6 batch, 01),
respectively. In both cases, the method yields crude complexes
that are not trypsinized prior to use. We have not checked
whether the preparations are M or L complex form, but
usually there are only M complexes in C. botulinum B.55 Pure
hemagglutinin free BoNT/B1 was purchased un-nicked from
Metabiologics Inc. (Madison, USA) with stated activity of 2 £
108 LD50.mg
¡1 (1 mg.mL¡1 from Okra strain) which was not
confirmed. All toxin preparations were not further trypsinized
and were diluted to 20,000 LD50.mL
¡1 in gelatin (0.2% w/v)
phosphate (50 mM di-sodium hydrogen orthophosphate) (GPB)
buffer, pH 6.5, and stored at ¡40C until use.
The polyvalent antitoxin used as positive control in same neu-
tralization assays is a F(ab)2 immunoglobulin fraction from ani-
mal immune serum and currently licensed in the European
Union by Novartis (Marburg, Germany). The activity of the
batch used (lot #079012A) was determined by the manufacturer:
the equine protein concentration was 27 mg.mL¡1 (85–90%
purity) and the labeled neutralization potency was »1000 IU.
mL¡1 against BoNT/A, »500 IU.mL¡1 against BoNT/B, and
»50 IU.mL¡1 against BoNT/E.
Animal immunization and ethical statement
Two different male cynomolgus macaques (Macaca fascicula-
ris) were immunized with 4 subcutaneous injections of 80 mg of
the recombinant C-terminus of BoNT/B2-HC from strain F11
(amino acids 861 to 1291, with a N-terminal 6xHis-tag from
pET28 vector) or with recombinant BoNT/B2-LC (amino acids
1 to 444, with a N-terminal 6xHis-tag from pET28 vector) in
Freund’s adjuvant, as previously described.56 Complete Freund’s
adjuvant was used for the primary immunization (Sigma, Isle
d’Abeau, France) and incomplete Freund’s adjuvant for the fol-
lowing injections. The first 3 injections were administered at
one-month intervals and the fourth injection was administered
4 months after the third (Fig. 1).
These animal experiments were approved and performed in
compliance with all relevant French ethical guidelines and laws,
in particular : 1) «Partie reglementaire du livre II du code rural
(Titre I, chapitre IV, section 5, sous-section 3: experimentation
sur l’animal)» ; 2) «Decret 87–848 du 19–10/1987 relatif aux
experiences pratiquees sur les animaux vertebres modifie par le
decret 2001/464 du 29/05/2001» ; 3) «Arrête du 29 octobre
1990 relatif aux conditions de l’experimentation animale pour le
ministere de la defense» ; and 4) «Instruction 844/DEF/DCSSA/
AST/VET du 9 avril 1991 relative aux conditions de realisation
de l’experimentation animale.”
The in vivo paralysis neutralization tests (Division of Bacteri-
ology Project License 80/2634) were performed in compliance
with the UK Home Office regulations for the use of animals in
research and testing under the Animals (Scientific Procedures)
Act 1986 (ASPA). ASPA was recently revised to transpose Euro-
pean Directive 2010/63/EU on the protection of animals used
for scientific purposes. The revised EU legislation came into force
on January 1, 2013. All experiments on animals at NIBSC (UK)
are also approved by the local animal research oversight commit-
tee AWERB (Animal Welfare and Ethics Review Body).
Library construction
After the final immunization, bone marrow was sampled twice
a week for 1 month, with sample volumes not exceeding 6 mL
each (Fig. 1). Total RNA was extracted using Tri Reagent
(Molecular Research Center Inc., Cincinnati, OH USA). RNA
coding Fd fragments of the g chain and k light chains were sepa-
rately retro-amplified with 9 and 7 specific primer sets, respec-
tively, and the best amplification was chosen to build the
library.52 The PCR products corresponding to the retro-amplifi-
cation of the RNA coding Fd fragments and the g chain and k
light chains were separately pooled to generate 2 sub-libraries in
pGEM-T vector (Promega, Madison, Wisconsin, USA): one
for the antibody variable region of the light chain (VL) and one
for the antibody variable region of the heavy chain (VH). The
DNA encoding the VL and VH regions were amplified, with 2
oligonucleotide primer sets introducing restriction sites.57 The
library construction consisted of the cloning of the VL fragments
into pHAL35 (BoNT/B2-LC library) or pHAL32 vector
(BoNT/B2-HC library),58 and then the cloning of the VH frag-
ments into the same vector, containing the VL repertoire. For
this, the pHAL35 or pHAL32 vector and the VL fragments were
digested with MluI and NotI (New England Biolabs, Frankfurt,
Germany), the enzymes were inactivated, pHAL35 or pHAL32
was dephosphorylated using calf intestinal phosphatase (MBI,
Fermentas), and the DNA was purified. VL PCR products
(270 ng) were inserted into 1 mg of the dephosphorylated
pHAL35 or pHAL32 preparation in 4 separate ligation reactions.
DNA was precipitated from the reaction mixes with ethanol and
sodium acetate, the pellet was washed twice with 70% ethanol,
and then 4 aliquots (25 mL) of XL1-Blue MRF’ (Stratagene,
Amsterdam, the Netherlands) were used for electroporation.
Plasmids (VL library) were isolated using a Plasmid Midi Kit
(QIAGEN, Hilden, Germany). The VL library and the VH
fragments were digested with NcoI and HindIII (New England
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Biolabs), and ligation and electroporation were then performed
as described for VL. The library was packaged into M13K07
phage (Agilent, Waldbron, Germany).
Selection of BoNT/B1 and BoNT/B2–HC and –LC
specific scFv using antibody phage display
Screening of scFvs against BoNT/B-HC and -LC was per-
formed in 2 steps. Because pure BoNT/B2 holotoxin was not
available for this study, the recombinant BoNT/B2-HC or
BoNT/B2-LC were used as a surrogate for BoNT/B2. In the first
step of panning, a plate (Nunc, Roskilde, Denmark) was coated
overnight at 4C with BoNT/B1 holotoxin (Metabiologics Inc.,
Madison, WI USA) at a concentration of 5 mg.mL¡1 in PBS.
The next day, the plate was saturated with PBS-BSA (3%) for
2 h at 37C and phage were incubated in the wells of plates for
2 h at 37C. Three rounds of panning, composed of 5, then 10
followed by 20 washes with 5 min interval between each were
performed in PBS-Tween (0.1%) as a washing buffer. An addi-
tional round of panning, composed of 20 washes, was performed
using the same conditions, except that BoNT/B2-HC or
BoNT/B2-LC (5 mg.mL¡1 in PBS) (Institute Pasteur, Paris)
were used as the coating antigen. After each round of panning
the plate was rinsed with sterile PBS, and the phage were eluted
with trypsin (10 mg.mL¡1 in PBS, 30 min at 37C). E. coli
(SURE strain), previously cultured in SB medium supplemented
with tetracycline (10 mg.mL¡1), were infected with the eluted
phage.
ScFv sequencing
One hundred clones were randomly handpicked after the
fourth round of panning and cultured in SB medium supple-
mented with carbenicillin (50 mg.mL¡1). DNAs were extracted
by the Nucleobond AX100 kit (Macherey-Nagel, Duren, Ger-
many) or the QIA cube apparatus (Qiagen, Hilden, Germany)
and then sequenced by Beckman Coulter Genomics
(Takeley, UK) using the primers MHLacZ-Pro_f
(50_GGCTCGTATGTTGTGTGG_30) and MHgIII_r
(50_CTAAAGTTTTGTCGTCTTTCC_30).59 The DNA
sequences were then translated to amino acid sequences (http://
web.expasy.org/translate/) to identify and eliminate the redun-
dant and the recombined sequences.
Production and purification of scFv and scFv-Fc
DNAs encoding the scFvs of interest were transformed into
the non-suppressor E.coli strain HB2151 in order to express and
purify soluble scFvs, as described previously.60
For scFv-Fc production, the mammalian expression vector
pCSE2.5-mIgG2c-XP was used for the fusion of scFv to the gene
fragment encoding the human IgG2 Fc part (hinge-CH2-CH3).
The expression was performed as described previously.61 In brief,
HEK293–6E cells (National Research Council, Biotechnological
Research Institute (BRI), Montreal, Canada) were cultured in
the chemically defined medium F17 (Invitrogen, Life Technolo-
gies, Darmstadt, Germany), supplemented with 1g.L¡1 pluronic
F-68 BioChemica (Applichem, Darmstadt, Germany), 4 nM L-
glutamine (PAA) and 25 mg.L¡1 G418 (PAA). DNA was
transiently transfected into 25 mL HEK293–6E cells in Erlen-
meyer shake flasks. After 48 hours cultivation at 110 rpm, 37C
and 5% CO2 atmosphere in a Minitron orbital shaker (Infors,
Bottmingen, Switzerland), one volume culture medium and a
final concentration of 0.5% (w/v) of tryptone N1 (TN1, Orga-
notechnie S.A.S., La Courneuve, France) was used for the purifi-
cation on a UNOsphereSUPrA column (Biorad) with a Profinia
apparatus (Biorad, Hercules), according to the manufacturer’s
instructions.
ELISA assays
During the course of immunization, the immune response in
macaques was evaluated by an ELISA method as described previ-
ously,60 except that in this study holotoxin BoNT/B1 (Metabio-
logics Inc., Madison, Wisconsin USA) or recombinant
BoNT/B2-LC or BoNT/B2-HC (Institut Pasteur, Paris) were
used instead of LF as coating antigen. Briefly, a Maxisorb
plate (Nunc, Roskilde, Denmark) was coated overnight with
5 mg.mL¡1 of each antigen in PBS (Euromedex, Mundolsheim,
France). After the coating, plates were saturated with PBS-BSA
(3%) for 2 h at 37C. The macaque serum was then incubated
for 2 h at 37C. The pre-immune serum was simultaneously
incubated as a negative control. The reactions were developed
with the anti-human-IgG (Fc specific)-HRP conjugated (Sigma
Aldrich, Isle d’Abeau, France) substrate diluted 1/1,000 in the
saturation buffer and incubated for 1 h at 37C. Specific color
was developed by addition of TMB (Sigma Aldrich, Isle d’Abeau,
France) and read at 650 nm without stopping the reaction. The
antibody titre was measured as the highest dilution of the
immune serum giving a signal 3 times stronger than the negative
control serum, at the same concentration.
For phage-ELISA, a Maxisorb plate (Nunc, Roskilde, Den-
mark) was coated overnight with 5 mg.mL¡1 of either BoNT/B1
holotoxin, BoNT/B2-LC, BoNT/B2-HC, KLH or PBS-BSA
(5%). Plates were then saturated in PBS-milk (3%) for 2 h at
37C. Phage were then diluted in PBS-milk (1%) and incubated
for 2 h at 37C. The reactions were developed with the anti-
M13-HRP-conjugated antibody (Amersham Biosciences, Little
Chalfont, United Kingdom) diluted 1/1,000 in the saturation
buffer. Plates were developed by addition of TMB substrate
(Sigma Aldrich, Isle d’Abeau, France) and read at OD 650 nm,
without stopping the reaction.
Affinity measurement and competition studies
Affinities of scFv and scFv-Fc antibodies were measured by
SPR using a Biacore 3000 instrument (General Electric Health-
care-Biacore, Uppsala, Sweden). Each scFv was immobilised
(600 RU) on a CM5 chip (Biacore) via amine coupling and at
least 4 dilutions (in HBS-EP buffer, Biacore) of BoNT/B1 holo-
toxin (from 0.16 mM to 0.01 mM), BoNT/B2-HC (from
0.5 mM to 0.06 mM) or BoNT/B2-LC (from 0.5 mM to
0.06 mM) were tested for at least 1,000 seconds. For scFv-Fc
measurements, BoNT/B1, BoNT/B2-HC or BoNT/B2-LC were
immobilized (1,000 RU) on the chip, and at least 4 dilutions of
the scFv-Fc in HBS-EP buffer (from 0.3 mM to 9 nM) were
tested for at least 1,000 seconds. All the measurements were
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performed under a flow rate of 30 ml.min¡1. Affinities were
calculated using the BIAevaluation software (General Electric
Healthcare-Biacore) according to Langmuir adsorption model
and results were verified by internal consistency tests.62
Competition studies were performed by the SPR using Bia-
core 3000 instrument (General Electric Healthcare-Biacore,
Uppsala, Sweden). The CM5 chip (Biacore) was first coated with
BoNT/B1 holotoxin (0.16 mM) followed by either scFv BL3 or
BLC42. This step was then followed by injection of either scFv
BLC42 or BLC3 without regeneration between injections of the
2 different antibodies. Both combinations were studied to inves-
tigate if these 2 antibodies compete for the same epitope on the
BoNT/B1 toxin.
Computational analysis
The sequences of interest were analyzed with IMGT/V-QUEST
and IMGT/DomainGapAlign tools, available on-line from the
International ImmunoGeneTics Information system (IMGT)
(http://imgt.imgt.org),53,63-65 to identify the human germline
sequences that are the most similar to the isolated scFvs and to cal-
culate the GI. The percentage of identity between the framework
regions of the isolated scFv and those of the most similar human
germline sequences, representing a first evaluation of immunoge-
nicity, was also calculated.52,53 A second evaluation of immunoge-
nicity relied on the G-score (http://www.bioinf.org.uk). This
parameter evaluates the “humanness” of a given variable region by
comparison with expressed human variable regions belonging to
the same family available from the Kabat database. Human vari-
able regions have an average G-score equal to 0; a G-score higher
than 0 indicates that a sequence has a similarity with human vari-
able region sequences higher than human average, and conversely
for G-scores lower than 0.38
In vitro inhibition of the BoNT/B endopeptidase activity
The principle of the endopeptidase assay for BoNT/B toxin is
the same as previously described for BoNT/A and BoNT/E,66
except that 35 amino acid VAMP2 peptide (amino acid VAMP2
60 to 94, purchased from Immune Systems Ltd, Paignton, UK),
is used to coat Sulfhydryl 96-well ELISA plates (Costar plates,
Corning Inc., NY USA) at 50 mL per well (2mg.mL¡1). The
positive signal in the immunoassay is associated with BoNT/B
cleavage of this substrate and is detected by an antibody to a
newly exposed epitope on VAMP2. This antibody was made in
house by immunization of rabbits with an octapeptide (VAMP2
amino acid sequence 77 to 84) conjugated to KLH through the
N-terminal Cys residue, purified from serum and used in the
assay at 60 mg.mL¡1.
Inhibition studies were performed to determine the concen-
trations at which scFvs could inhibit the endopeptidase activity
conferred by a fixed dose of BoNT/B1 or BoNT/B2 subtype.
The fixed toxin concentrations for inhibition studies were deter-
mined from dose response curves for each subtype (Fig. S2).
Doses of toxin representing maximum activity were selected: for
pure BoNT/B1 (Metabiologics, USA), a dose of 30 LD50.mL
¡1
was selected; for complex BoNT/B1 and BoNT/B2 (Institut
Pasteur, Paris), 10 LD50.mL
¡1 and 0.2 LD50.mL¡1 were
selected, respectively. All toxins were diluted in reaction buffer
(50 mM HEPES, 20 mM ZnCl2, 5 mM DTT, pH 7.0) and
mixed with an equal volume of a graded concentration of scFvs
against the BoNT/B-LC. The toxin:scFv mixtures were briefly
shaken on a plate shaker for 1 min at room temperature and
incubated for 1 h at 37C prior to transfer (50 mL per well) to
35 amino acid VAMP2 peptide coated sulfhydryl plate for esti-
mation of endopeptidase activity. Plates were incubated for 18 h
at room temperature and then washed 3 times with PBS supple-
mented with 0.05% (v/v) Tween 20. Reaction was detected by
addition of 50 mL per well of a purified rabbit antibody to
VAMP2 (77–84) at 60 mg.mL¡1 diluted in 2.5% (w/v) skimmed
milk powder in PBS (MPBS). After 1 h incubation at room tem-
perature, the plate was washed with PBS supplemented with
0.05% (v/v) Tween 20 and 100 mL per well of goat anti-rabbit
(Sigma A0545) detection antibody (1/2000, diluted in 2.5%
MPBS) was added and plates incubated again for 1.5 h at room
temperature. After a final washing, ABTS substrate solution
(2,20-azino-bis(3-ethylben-zothiazoline-6-sulfonic acid) diammo-
nium salt, 0.05% (v/v) of 30% (w/v) hydrogen peroxide solution,
50 mM citric acid pH 4.0) was added at 100 mL per well. The
color reaction was evaluated by determining absorbance at
405 nm with a plate reader (Multiskan MS, Labsystems).
To allow comparison between preparations, all antibody
fragments were diluted to the same initial concentration of
10 mg.mL¡1 and serial doubling dilutions were made from this
concentration. ScFv targeting BoNT/A-LC and inhibiting
BoNT/A1 toxin31 was included in the assays at the same concen-
tration as a negative control.
Ex vivo mouse phrenic nerve neutralization studies
Mouse phrenic nerve-hemidiaphragm (MPNH) preparation
and neutralization studies were performed as described previ-
ously.26,32 Briefly, left phrenic nerve-hemidiaphragm prepara-
tions were excised from male BALB/c strain of mice and installed
in a 6 mL organ bath maintained at 37C containing Krebs-gela-
tin buffer gassed with O2 95% / CO2 5%. Indirect stimulation
via the phrenic nerve was achieved with a supramaximal voltage
(»3 V, 1 Hz, 0.2 ms) and the resulting muscle contractions
were measured with an isometric force transducer (FMI Gmbh,
Seeheim, Germany) linked to a ML110 bridge amplifier and a
Powerlab/4SP 4 channel recorder (AD Instruments, Chalgrove,
UK). The hemidiaphragm resting tension was increased in a step-
wise manner during the equilibration period until reproducible
twitches were observed. Once the muscle twitch response to nerve
stimulation had stabilized and remained at a constant magnitude
for at least 30 min without further adjustment, the Krebs buffer
was replaced with 6 mL of fresh Krebs buffer containing the
toxin, and stimulation was resumed.
Toxin-induced paralysis was defined as a 50% decrease in the
muscle twitch response to neurogenic stimulation, based on
the magnitude of the contractions just before the addition of the
toxin. The time to 50% paralysis after the addition of BoNT/B1
or BoNT/B2 was determined by fitting the linear part of the
paralysis curve. The myotoxic effects of the toxin were also
assessed by applying a short burst of direct (muscle) stimulation
1174 Volume 7 Issue 6mAbs
(»30 V, 1 Hz, 1 ms) before adding the toxin at the end of the
experiment.
Dose response curves for BoNT/B2 serotype were established
to identify the optimum concentration of toxin suitable for the
neutralization studies. The toxin dose selected as optimum for
antibody inhibition studies typically induces »80% of the maxi-
mum paralytic activity in the dose response curve (ensuring
optimal precision) unless further scFv characterization requires
weaker paralytic activity (Fig. 2).
A dose of 100 LD50.mL
¡1 pure BoNT/B1 (Metabiologics,
USA) and a dose of 0.2 LD50.mL
¡1 complex BoNT/B2 (Institut
Pasteur, Paris) were selected as inducing equivalent paralysis in
the MPNH. Toxin neutralization was assessed by pre-mixing
500 pg.mL¡1 (100 LD50.mL
¡1) of pure BoNT/B1, or
2.9 ng.mL¡1 (0.2 LD50.mL
¡1) of complex BoNT/B2, with the
various concentrations of either scFv or scFv-Fc preparations,
and incubating for 30 min at 37C before applying the mixture
to the tissue.
Linear and non-linear regression analyses were performed with
Prism 5.0 software (Graphpad, San Diego, CA, USA). The neu-
tralization of toxin activity was proportional to the ability of the
antibody fragments (scFv or scFv-Fc) to delay BoNT/B-induced
paralysis. Greater antibody neutralizing potency was associated
with the requirement of a longer period of time for the hemi-
diaphragm to reach 50% paralysis for the same dose of toxin. In
some studies, commercial trivalent botulinum antitoxin was
included as a positive control to provide an indication of protec-
tive activity.
In vivo neutralization studies in mouse flaccid paralysis assay
Botulinum toxin induces asymmetric flaccid muscular paraly-
sis at the site of injection and this has formed the basis for devel-
opment of an assay for toxin and serotype specific
neutralization.67,68 The method was further validated against the
mouse LD50 test for neutralization of BoNT/A by specific IgG
and its smaller fragments.27
Neutralization activity of selected scFv-Fcs (BLC3 and B2–7)
was assessed in vivo, both individually and in combination, by
pre-mixing complex BoNT/B2 (0.2 LD50 per dose) with the vari-
ous concentrations of each antibody (0.25 mg, 2.5 mg and 25 mg
per dose). For the combination protocol, 2 antibodies were used
at 0.25 mg each and were mixed with the same dose of complex
BoNT/B2 toxin. All dilutions were prepared in gelatin
(0.2% w/v) phosphate (50 mM di-sodium hydrogen orthophos-
phate buffer, GPBS, pH 6.5), and toxin:antibody mixtures were
left for 30 min at room temperature before injecting 0.1 mL
subcutaneously into female MF1 strain of mice, each weighing
between 16–20 g (n D 4 per dose). All injections were performed
within 30 min and all the mice were injected in the left inguinoc-
rural region. Scores were recorded at 24 and 48 h post injection
with intensity of paralysis ranging from 0 (no sign of paralysis),
to scores between 1 and 4, defined by an increasing extent of local
flaccid paralysis. Positive control group of mice were injected
with BoNT/B2 toxin alone, and negative control group of mice
were injected with the maximum concentration of antibody used
in the assay in the absence of toxin. In preliminary studies,
the International Standard for type B antitoxin (NIBSC code
60/001, 2400 IU/ampoule) was used to confirm specific neutrali-
zation (data not shown).
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